西格列汀对2型糖尿病空腹血糖及胰岛β细胞功能影响研究
|
摘要
目的探讨西格列汀对2型糖尿病患者空腹血糖及胰岛β细胞功能影响。方法收集本院90例2017年6月至2018年1月2型糖尿病患者。随机分组,对照组予以甘精胰岛素治疗,观察组则予以甘精胰岛素联合西格列汀治疗,比较结果。结果观察组临床疗效高于对照组(P<0.05);观察组血糖控制至达标的天数优于对照组(P<0.05);治疗前两组空腹血糖情况、甘油三酯、总胆固醇差异均无统计学意义;治疗后观察组空腹血糖情况、甘油三酯、总胆固醇优于对照组(P<0.05)。治疗前两组胰岛β细胞功能并无明显差异;治疗后观察组胰岛β细胞功能优于对照组(P<0.05)。观察组低血糖率低于对照组(P<0.05)。结论甘精胰岛素联合西格列汀治疗2型糖尿病的临床疗效确切,可更好改善空腹血糖情况、甘油三酯、总胆固醇、胰岛β细胞功能,值得推广应用。
Objective To investigate the effect of sitagliptin on type 2 diabetes mellitus and its effect on islet β cell function. Methods 90 patients with type 2 diabetes from June 2017 to January 2018 were enrolled in our hospital. Randomly grouped, the control group was treated with insulin glargine, and the observation group was treated with insulin glargine plus sitagliptin. The clinical efficacy of the two groups was compared; the number of days of blood glucose control reached the standard; the fasting blood glucose level, triglyceride and total cholesterol before and after treatment; the islet β-cell function related indicators before and after treatment; the hypoglycemia rate. Results The clinical efficacy of the observation group was higher than that of the control group(P<0.05). The number of days of blood glucose control in the observation group was better than that of the control group(P<0.05). There was no significant difference in fasting blood glucose, triglyceride and total cholesterol between the two groups before treatment. After treatment, the fasting blood glucose, triglyceride and total cholesterol in the observation group were better than the control group(P<0.05). There was no significant difference in islet β-cell function between the two groups before treatment. After treatment, the islet β-cell function was better than the control group(P<0.05). The hypoglycemia rate of the observation group was lower than that of the control group(P<0.05). Conclusion The clinical efficacy of insulin glargine combined with sitagliptin in the treatment of type 2 diabetes is better, which can improve the fasting blood glucose, triglyceride, total cholesterol and islet β cell function. It is worthy of popularization and application.
Objective To investigate the effect of sitagliptin on type 2 diabetes mellitus and its effect on islet β cell function. Methods 90 patients with type 2 diabetes from June 2017 to January 2018 were enrolled in our hospital. Randomly grouped, the control group was treated with insulin glargine, and the observation group was treated with insulin glargine plus sitagliptin. The clinical efficacy of the two groups was compared; the number of days of blood glucose control reached the standard; the fasting blood glucose level, triglyceride and total cholesterol before and after treatment; the islet β-cell function related indicators before and after treatment; the hypoglycemia rate. Results The clinical efficacy of the observation group was higher than that of the control group(P<0.05). The number of days of blood glucose control in the observation group was better than that of the control group(P<0.05). There was no significant difference in fasting blood glucose, triglyceride and total cholesterol between the two groups before treatment. After treatment, the fasting blood glucose, triglyceride and total cholesterol in the observation group were better than the control group(P<0.05). There was no significant difference in islet β-cell function between the two groups before treatment. After treatment, the islet β-cell function was better than the control group(P<0.05). The hypoglycemia rate of the observation group was lower than that of the control group(P<0.05). Conclusion The clinical efficacy of insulin glargine combined with sitagliptin in the treatment of type 2 diabetes is better, which can improve the fasting blood glucose, triglyceride, total cholesterol and islet β cell function. It is worthy of popularization and application.
引文
[1]张青.用二甲双胍联合西格列汀对25例2型糖尿病患者进行治疗的效果评价[J].当代医药论丛,2018,2(14):141-142.
[2]周宗爱,陈年由,汤智越,等.西格列汀治疗2型糖尿病的临床疗效及其对血清葡萄糖转运蛋白4的影响[J].中国临床药理学杂志,2015,31(7):491-494.
[3]孔霞,路盈.磷酸西格列汀对2型糖尿病患者血糖、血脂及胰岛素抵抗的影响[J].糖尿病新世界,2018,21(10):67-68.
[4]祝菁菁,陈文.西格列汀治疗2型糖尿病的药物经济学研究[J].中国药房,2016,27(2):157-162.
[5]傅惠媛.西格列汀治疗2型糖尿病的疗效及对患者胰岛β细胞功能的影响分析[J].糖尿病新世界,2018,21(2):67-68.
[6]李玉苏,窦连军,王犇,等.西格列汀治疗2型糖尿病的疗效及对胰岛β细胞功能的影响的观察[J].贵州医药,2017,41(12):1273-1275.
[7] Morling Joanne R, Fallowfield Jonathan A, Williamson Rachel M, et al. gamma-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2diabetes mellitus:the Edinburgh Type 2 Diabetes Study[J]. Diabetologia:Clinical and Experimental Diabetes and Metabolism=Organ of the European Association for the Study of Diabetes(EASD), 2015, 58(7):1484-1493.
[8]陈金逸,符茂雄.西格列汀联合预混胰岛素治疗2型糖尿病的效果及其对血糖波动的影响[J].重庆医学,2016,45(35):4989-4991.
[9]李寅辉,李凯利,刘浩.西格列汀治疗2型糖尿病药理作用的Meta分析[J].循证医学,2015,15(3):149-154.
[10]梁勇前,刘湘茹,胡德龙,等.瑞格列奈或西格列汀联合甘精胰岛素治疗初发2型糖尿病疗效观察[J].现代医院,2015,15(6):29-31,34.
[11]曹晓红,张新星.阿卡波糖联合磷酸西格列汀治疗老年2型糖尿病疗效及对患者肠道菌群的影响[J].世界华人消化杂志,2015,23(15):2507-2511.
[12]王仙花,邵卉,何建影,等.二肽基肽酶Ⅳ抑制剂西格列汀2型糖尿病治疗领域新进展[J].中华保健医学杂志,2012,14(6):494-495.
[2]周宗爱,陈年由,汤智越,等.西格列汀治疗2型糖尿病的临床疗效及其对血清葡萄糖转运蛋白4的影响[J].中国临床药理学杂志,2015,31(7):491-494.
[3]孔霞,路盈.磷酸西格列汀对2型糖尿病患者血糖、血脂及胰岛素抵抗的影响[J].糖尿病新世界,2018,21(10):67-68.
[4]祝菁菁,陈文.西格列汀治疗2型糖尿病的药物经济学研究[J].中国药房,2016,27(2):157-162.
[5]傅惠媛.西格列汀治疗2型糖尿病的疗效及对患者胰岛β细胞功能的影响分析[J].糖尿病新世界,2018,21(2):67-68.
[6]李玉苏,窦连军,王犇,等.西格列汀治疗2型糖尿病的疗效及对胰岛β细胞功能的影响的观察[J].贵州医药,2017,41(12):1273-1275.
[7] Morling Joanne R, Fallowfield Jonathan A, Williamson Rachel M, et al. gamma-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2diabetes mellitus:the Edinburgh Type 2 Diabetes Study[J]. Diabetologia:Clinical and Experimental Diabetes and Metabolism=Organ of the European Association for the Study of Diabetes(EASD), 2015, 58(7):1484-1493.
[8]陈金逸,符茂雄.西格列汀联合预混胰岛素治疗2型糖尿病的效果及其对血糖波动的影响[J].重庆医学,2016,45(35):4989-4991.
[9]李寅辉,李凯利,刘浩.西格列汀治疗2型糖尿病药理作用的Meta分析[J].循证医学,2015,15(3):149-154.
[10]梁勇前,刘湘茹,胡德龙,等.瑞格列奈或西格列汀联合甘精胰岛素治疗初发2型糖尿病疗效观察[J].现代医院,2015,15(6):29-31,34.
[11]曹晓红,张新星.阿卡波糖联合磷酸西格列汀治疗老年2型糖尿病疗效及对患者肠道菌群的影响[J].世界华人消化杂志,2015,23(15):2507-2511.
[12]王仙花,邵卉,何建影,等.二肽基肽酶Ⅳ抑制剂西格列汀2型糖尿病治疗领域新进展[J].中华保健医学杂志,2012,14(6):494-495.